Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MYOTONACHOL vs DUVOID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Myotonachol (bethanechol chloride) is a direct-acting parasympathomimetic agent that selectively stimulates muscarinic acetylcholine receptors, particularly M3 subtypes, in smooth muscle of the gastrointestinal tract and urinary bladder. It mimics the action of acetylcholine but is resistant to hydrolysis by acetylcholinesterase, leading to increased smooth muscle tone and peristalsis.
Selective alpha-1A adrenergic receptor antagonist; relaxes smooth muscle in the bladder neck and prostate, reducing outflow resistance.
FDA-approved: Treatment of acute postoperative and postpartum nonobstructive urinary retention and neurogenic atony of the bladder.,Off-label: Treatment of gastroesophageal reflux disease; management of chronic intestinal pseudo-obstruction; treatment of xerostomia (dry mouth) in Sjögren's syndrome or radiation-induced.
Benign prostatic hyperplasia (BPH) - treatment of symptoms,Off-label: None established
25 mg orally three times daily. Maximum dose 100 mg four times daily.
100 mg orally three times daily.
Terminal elimination half-life: 1.5-2.5 hours (prolonged in renal impairment).
Terminal elimination half-life is 12–15 hours in patients with normal renal function; prolonged to 24 hours or more in moderate-to-severe renal impairment.
Bethanechol is primarily metabolized via hydrolysis by plasma esterases (pseudocholinesterases) to inactive metabolites. Minimal hepatic metabolism occurs.
Extensively metabolized in the liver primarily by CYP2D6 and CYP3A4, with possible minor contributions from other CYPs.
Renal: 70-80% unchanged; biliary/fecal: 20-30% as metabolites.
Renal elimination accounts for approximately 90% of a dose as unchanged drug; biliary/fecal excretion is minor (<10%).
~30%, bound primarily to albumin.
Approximately 50–70% bound to plasma proteins, primarily albumin.
0.3-0.6 L/kg, indicating distribution into total body water.
Vd approximately 0.6 L/kg, indicating distribution into total body water.
Oral: 10-20% (extensive first-pass metabolism); Subcutaneous: ~80%; Intravenous: 100%.
Oral: 75–85% (may be decreased with food); subcutaneous: nearly 100%.
GFR 30-59 m L/min: 25 mg twice daily. GFR 15-29 m L/min: 25 mg once daily. GFR <15 m L/min: not recommended.
GFR 30-89 m L/min: no adjustment; GFR <30 m L/min: avoid use.
Child-Pugh A: no adjustment. Child-Pugh B: 25 mg twice daily. Child-Pugh C: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 50 mg twice daily; Child-Pugh C: avoid use.
0.5-1 mg/kg orally three times daily; maximum 25 mg per dose.
Not recommended for use in pediatric patients.
Start at 25 mg twice daily due to increased anticholinergic sensitivity.
Initial dose 50 mg twice daily; titrate cautiously due to increased anticholinergic sensitivity.
None
None.
May cause reflex tachycardia due to hypotension; caution in patients with coronary artery disease, bradycardia, or recent myocardial infarction. Increased vagal tone may precipitate asthma attacks; avoid in asthmatics. May cause exacerbation of peptic ulcer disease. Can increase ureteral pressure; avoid in ureteral obstruction. Use cautiously in patients with epilepsy or hyperthyroidism. Monitor for cholinergic crisis (salivation, lacrimation, urination, defecation, emesis).
Orthostatic hypotension (especially dose-related; syncope reported),Intraoperative floppy iris syndrome (IFIS) during cataract surgery,Priapism (rare),Dizziness, somnolence, and fatigue may occur,Use caution with hepatic impairment,Avoid use with strong CYP3A4 inhibitors or inducers
Absolute: Hypersensitivity to bethanechol; mechanical obstruction of the gastrointestinal or urinary tract; recent gastrointestinal anastomosis or bladder surgery; hyperthyroidism; peptic ulcer disease; asthma; epilepsy; Parkinsonism; hypotension; bradycardia; coronary artery disease. Relative: Pregnancy (C); nursing mothers; patients with vagotonia or receiving quinidine or procainamide.
Hypersensitivity to DUVOID or any component,Moderate to severe hepatic impairment (Child-Pugh class B or C),Use with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir)
Food decreases absorption; take on an empty stomach. Avoid high-fat meals as they may increase side effects. No known specific food interactions.
Take on an empty stomach; food may decrease absorption. Avoid alcohol as it may increase cholinergic side effects.
Pregnancy Category C. First trimester: Animal studies show fetal resorption and skeletal anomalies at doses 2-3 times the maximum recommended human dose. No adequate human studies. Second trimester: Potential for premature labor due to cholinergic stimulation. Third trimester: Increased risk of uterine hyperstimulation and fetal distress if used for labor induction. Avoid use during pregnancy unless clearly needed.
DUVOID (bethanechol) is classified as FDA Pregnancy Category C. No adequate studies in pregnant women. Animal reproduction studies have not been conducted. Fetal risk cannot be ruled out. Use only if potential benefit justifies potential risk to fetus. No known specific trimester risks.
Excreted in human milk in low concentrations. M/P ratio not established. Caution advised. Potential for cholinergic adverse effects in the infant (e.g., diarrhea, increased secretions). Use only if benefit outweighs risk.
It is not known whether bethanechol is excreted in human milk. Caution should be exercised when administered to a nursing woman. M/P ratio is unknown.
No standard dose adjustments recommended due to limited pharmacokinetic data in pregnancy. However, increased plasma volume and renal clearance may necessitate dose titration based on clinical response. Use lowest effective dose and monitor for maternal cholinergic toxicity.
No formal pharmacokinetic studies in pregnancy. Due to increased plasma volume and renal clearance, dose adjustments may be necessary but specific recommendations are lacking. Use lowest effective dose and monitor clinical response.
MYOTONACHOL (bethanechol) is a cholinergic agonist used for urinary retention. Monitor for bradycardia and bronchospasm, especially in patients with asthma or cardiac disease. Administer on an empty stomach to reduce nausea. Avoid use in patients with GI obstruction or recent bladder surgery. Atropine should be readily available as an antidote.
DUVOID (bethanechol) is a cholinergic agonist used for urinary retention. Monitor for cholinergic crisis (excessive salivation, sweating, bradycardia). Administer on an empty stomach to reduce GI upset. Avoid in patients with asthma, hyperthyroidism, peptic ulcer disease, or epilepsy. Atropine is the antidote for overdose.
Take this medication on an empty stomach, 1 hour before or 2 hours after meals.,Avoid alcohol and caffeine, as they may worsen side effects.,Report symptoms like slow heart rate, wheezing, dizziness, or excessive sweating.,Do not drive or operate heavy machinery until you know how this drug affects you.,If you miss a dose, skip it and take the next dose at the regular time; do not double the dose.
Take this medication on an empty stomach, 1 hour before or 2 hours after meals.,Report any signs of excessive sweating, salivation, or bradycardia to your healthcare provider.,Avoid driving or operating machinery until you know how this drug affects you.,Do not stop taking this medication abruptly; consult your doctor for dose adjustments.,Keep a list of all medications you take and share with your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MYOTONACHOL vs DUVOID, answered by our medical review team.
MYOTONACHOL is a Cholinergic Agonist that works by Myotonachol (bethanechol chloride) is a direct-acting parasympathomimetic agent that selectively stimulates muscarinic acetylcholine receptors, particularly M3 subtypes, in smooth muscle of the gastrointestinal tract and urinary bladder. It mimics the action of acetylcholine but is resistant to hydrolysis by acetylcholinesterase, leading to increased smooth muscle tone and peristalsis.. DUVOID is a Cholinergic Agonist that works by Selective alpha-1A adrenergic receptor antagonist; relaxes smooth muscle in the bladder neck and prostate, reducing outflow resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MYOTONACHOL and DUVOID depend on the specific clinical indication. These are both Cholinergic Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MYOTONACHOL is: 25 mg orally three times daily. Maximum dose 100 mg four times daily.. The standard adult dose of DUVOID is: 100 mg orally three times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MYOTONACHOL and DUVOID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MYOTONACHOL is classified as Category C. Pregnancy Category C. First trimester: Animal studies show fetal resorption and skeletal anomalies at doses 2-3 times the maximum recommended human dose. No adequate human studies.. DUVOID is classified as Category C. DUVOID (bethanechol) is classified as FDA Pregnancy Category C. No adequate studies in pregnant women. Animal reproduction studies have not been conducted. Fetal risk cannot be rul. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.